Browse by Category
Browse by Location
Search
Tag Cloud
anthrax Strategic National Stockpile Training exercise Bioterror Biomagnetics National Research Council Homeland Security Biodefense lab Army Medical Research Institute antibiotics Emergency preparedness research Bioweapons NIAID smallpox Detection technology CDC TSA Defense Dept IAEM FEMA immunization Ebola Ricin Hendra Plague treaty West Nile Camouflage Paint Marburg antidote weapons destruction Sarin VHF viruses chemical disposal dna technology prevention Robotics Technology research grants tularemia weapons control foot and mouth disease decontamination E. coli Iraq missile defenseSubscribe to our newsletter
RSS Feed
Major smallpox vaccine order announcement expected
by Paul Tinder on November 27, 2009
Smallpox
The biodefense company SIGA Technologies, which engages in the discovery, development and commercialization of products for use in defense against biological warfare agents, is expected to make a major announcement about government orders of its product soon.
SIGA announced in May that it had submitted a response to the Biomedical Advance Research and Development Authority about the agency's outstanding RFP for the procurement of 1.7 million courses of a smallpox antiviral.
The inhaled smallpox virus is considered by the United States government to be the single biggest biological threat to the nation's citizens in the event of a biological attack by terrorists.
SIGA applies viral and bacterial genomics as well as sophisticated computational modeling to design and develop novel products with the intention of preventing and treating serious infectious diseases. SIGA places a special emphasis on products for defense against biological warfare.
In addition to its smallpox vaccine, SIGA has developed antiviral programs that target such Category A pathogens as arenaviruses - including Lassa fever, Junin, Machupo, Guanarito, Sabia and lymphocytic choriomeningitis - dengue virus and the filoviruses Ebola and Marburg.
SIGA has worked with the National Institutes of Health, the Department of Defense and other federal agencies in advancing its novel countermeasures to prevent and treat serious biological warfare diseases.
More News
- Soligenix announces heightened stability for RiVax
- New study shed light on how citizens will react to bio-outbreak
- Deep-UV could hold key to fighting bioattacks
- Kansas lauds proposed $40 million for biodefense facility
- Experts expect CBRN attack on U.S. within six months
- Study begins to find more effective manner of fighting smallpox
- Scott Habig joins Human Genome Sciences
- Sebelius responds to president's 2011 HHS budget
- Missile interceptor fails in mock attack
- Las Vegas expected to approve grants to fight bioterror
Read all news